SecBot SecBot
SECBOTREPLAY Home › Report › TIL

TIL · Instil Bio reported Q2 2026 results with a GAAP net loss of $0.63 per…

Instil Bio, Inc. · 8-K filed Aug 13, 2026 at 16:59 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Aug 13, 2026 at 16:59 ET

Instil Bio reported Q2 2026 results with a GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025, driven by sharply lower operating expenses as the company maintains a lean cash-burn structure while evaluating acquisition and in-licensing opportunities. Cash and marketable securities stood at $69.9M, down from $76.3M at year-end 2025, but management expects this to fund operations beyond 2027. The filing is routine for a pre-revenue biotech with no pipeline catalysts, the stock's direction hinges entirely on whether a transaction materializes, not on the quarterly loss trajectory.

  • GAAP net loss per share was $0.63 for Q2 2026, vs $3.24 in Q2 2025
  • Cash, cash equivalents, restricted cash and marketable securities totaled $69.9M as of June 30, 2026
  • Cash runway expected to fund operating plan beyond 2027
  • R&D expenses fell to $0.3M in Q2 2026 from $6.7M in Q2 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access